59
Participants
Start Date
August 12, 2013
Primary Completion Date
September 28, 2018
Study Completion Date
September 29, 2018
nilotinib
Nilotinib will be provided as 150 mg capsules. Patients will take nilotinib 300mg twice daily on study and dose modifications to 450mg once daily is permitted per protocol.
Memorial Sloan Kettering Memorial Sloan Kettering (63), New York
Weill Cornell Medical Center Dept. of Oncology, New York
Columbia University Medical Center Herbert Irving Pavilion, New York
Montefiore Medical Center Montefiore Medicial Center, The Bronx
Westchester Medical Center NY Medical College, Valhalla
University of Rochester Medical Center, Rochester
University of Virginia, Charlottesville
West Virginia University/ Mary Babb Randolph Cancer Center Mary Babb Randolph Cancer Ctr, Morgantown
Wake Forest University Health Sciences Hematology and Oncology, Winston-Salem
Duke University Medical Center Duke University Med Ctr, Durham
Carolina Oncology Specialists, PC, Hickory
University of South Carolina-Hollings Cancer Center Medical University of SC, Columbia
MD Anderson Cancer Center - Orlando Cancer Center, Orlando
H Lee Moffitt Cancer Center and Research Institute H. Lee Moffitt Cancer Ctr (67), Tampa
Florida Cancer Specialists DeptofFloridaCancerSpecialists, Fort Myers
University of Alabama Comprehensive Cancer Center University of Alabama (8), Birmingham
Tennessee Oncology Dept. of Centennial Medical, Nashville
Vanderbilt Univeristy Ingram Cancer Center (10), Nashville
Ohio State Comprehensive Cancer Center/James Cancer Hospital OSU Medical Center, Columbus
University of Iowa Hospitals and Clinics Holden Comprehensive Cancer Ct, Iowa City
Medical College of Wisconsin Med College of WI, Milwaukee
Billings Clinic Billings Clinic (8), Billings Montana
Stroger Cook County Hospital Division of Hematology & Onc, Chicago
University of Chicago Medical Center, Chicago
University of Kansas Hospital and Medical Center Clinical Research Center, Kansas City
Christus Schumpert Health System, Shreveport
Highlands Oncology Group, Fayetteville
Texas Oncology Texas Oncology - McAllen, Dallas
Texas Oncology Texas Oncology - Plano West, Dallas
Texas Oncology P A Texas Oncology - Midland, Dallas
Waco Cancer and Research Center, Waco
Oncology Consultants Oncology Consultants, P.A., Houston
The Methodist Hospital Cornell University, Houston
Brooke Army Medical Center Brooke Army Medical, San Antonio
South Texas Cancer Center- McAllen, McAllen
Hendrick Cancer Center Hendricks Cancer Center, Abilene
Rocky Mountain Cancer Centers USOR, Boulder
University of Utah / Huntsman Cancer Institute Huntsman Cancer Center, Salt Lake City
Banner MD Anderson Cancer Center Banner MD Anderson (2), Gilbert
Scottsdale Healthcare/TGen Clinical Research Service SC, Scottsdale
Compassionate Care Research Group Inc CCCMG, Fountain Valley
St Joseph Heritage Healthcare, Santa Rosa
Epic-Care, Pleasant Hill
Northwest Cancer Specialists Compass Oncology -BKM, Portland
Kadlec Clinic Hematology and Oncology SC, Kennewick
City of Hope National Medical Center Dept of Oncology, Duarte
UC San Diego UC San Diego Cancer Ctr, La Jolla
Wilshire Oncology Medical Group Corona Cancer Center, Multiple Locations
Michigan State University / Breslin Cancer Center Breslin Cancer Center (3), Lansing
Sutter Institute for Medical Research Oncology/Hematology, Sacramento
Cancer Center of Kansas, Wichita
Hackensack University Medical Center John Theurer Cancer Center, Hackensack
Hematology Oncology Associates of Northern New Jersey PA Dept of Hem-Onc of Northern NJ, Morristown
University of Texas Medical Branch SC, Galveston
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY